Two patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2037
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2039.20252029203320372039
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Dec 2037 · High confidence
Also notable
Ends May 2039 · High confidence
Lebecetin, a C-Type Lectin, as Neovascularization Inhibitor
US 11,191,807
Granted 2021. Computed term ends 2037.
Multi-Epitopic Peptide Compounds and Vaccines Against Leishmaniasis
US 11,559,575
Granted 2023. Computed term ends 2039.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Multi-Epitopic Peptide Compounds and Vaccines Against Leishmaniasis | 1 in force | to May 2039 |
| Lebecetin, a C-Type Lectin, as Neovascularization Inhibitor | 1 in force | to Dec 2037 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,191,807 | Lebecetin, a C-Type Lectin, as Neovascularization Inhibitor held by Sorbonne Université, Centre National de la Recherche Scientifique, Inserm (Institut National de la Santé et de la Recherche Medicale) and Institut Pasteur de Tunis In force · High confidence | In force | High confidence | |
| US 11,559,575 | Multi-Epitopic Peptide Compounds and Vaccines Against Leishmaniasis In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 3 patents ended · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.